GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCT
NCT ID: NCT03039049
Last Updated: 2017-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
328 participants
INTERVENTIONAL
2014-03-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT
NCT02053779
Early Preparation With Gonadotropin- Releasing Hormon (GnRh) Agonists Injection With Frozen-Thawed Embryo Transfer?
NCT03353883
GnRH Agonist and Intrauterine Insemination
NCT00503217
Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days
NCT01093443
GnRh Antagonist Protocol With Delayed Start Stimulation in Patients With Poor Ovarian Response
NCT03134690
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, a risk difference of 7% in delivery rates is still in favor of HCG trigger. Thus, further modifications in the luteal phase supplementation are required in order to optimise the reproductive outcome after GnRH-agonist triggering.
Recently, many papers showed, that independently of the GnRH analogue used to prevent the premature LH surge, the addition of GnRH-agonist during the luteal phase seems to be beneficial in terms of pregnancy. Nevertheless, their use in practice is not yet admitted because of controversial results in terms of efficacy and safety particularly on the conceptus.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GnRH agonist
Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.
Other Names:
• Decapeptyl 0.1 mg
Triptorelin 0.1 mg
a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
Control
No intervention
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Triptorelin 0.1 mg
a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Fertilization failure
* Severe endocrinopathy
* Azoospermia
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Ibn Rochd
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
benmachiche abdelhamid
Dr benmachiche abdelhamid, private infertility centre, Ibn rochd, constantine, Algeria
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abdelhamid Benmachiche, M.D
Role: PRINCIPAL_INVESTIGATOR
Ibn roch infertility centre, cité boussouf, Constantine Algeria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ibnrochd Clinic
Constantine, , Algeria
Ibnrochd IVF center
Constantine, , Algeria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02053779
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.